Marina Maslovaric, MD
Gynecology · Newport Beach, CANPI 1881922060
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,703 of the $2,263 with a category attached, or 75.2%. It is spread thinly across 24 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $931 and has fallen 86.5% since, to $126 in 2025.
Across 83 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Celularity Inc.$500
- AbbVie$481
- Boston Scientific$255
- Exeltis, USA Inc.$111
- Coopersurgical, Inc.$106
- Bayer$88
- plus $723 from 18 others
What the payments were for
- Speaking & faculty fees$50022%
- Food & beverage$1,70375%
- Education$603%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Celularity Inc. | 2 | $500 |
| AbbVie(2 entities) | 25 | $481 |
| Boston Scientific | 2 | $255 |
| Exeltis, USA Inc. | 6 | $111 |
| Coopersurgical, Inc. | 6 | $106 |
| Bayer | 5 | $88 |
| Hologic Sales And Service, LLC | 5 | $84 |
| Therapeuticsmd, Inc. | 5 | $82 |
| Roche Diagnostics Corporation | 3 | $60 |
| AMAG Pharmaceuticals, Inc. | 3 | $60 |
| Mayne Pharma Commercial LLC | 2 | $58 |
| Evofem Biosciences, Inc. | 3 | $53 |
| Aspira Women's Health Inc | 2 | $44 |
| Myovant Sciences Inc. | 2 | $41 |
| Pfizer | 2 | $41 |
| Exact Sciences | 2 | $36 |
| Astellas Pharma US Inc | 1 | $33 |
| Dexcom, Inc. | 1 | $33 |
| Biogen | 1 | $23 |
| Medicem Inc. | 1 | $16 |
| Ascend Therapeutics US, LLC | 1 | $15 |
| Dysis Medical, Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$2,263 in reported general payments places this provider in the 70th percentile of 247 gynecology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 47 | $4,896 |
| Estradiol (Twice Weekly)Estradiol | 19 | $2,782 |
| Estradiol (Once Weekly)Estradiol | 16 | $2,679 |
| YuvafemEstradiol | 13 | $2,422 |
| ProgesteroneProgesterone, Micronized | 50 | $2,263 |
| ValacyclovirValacyclovir Hcl | 15 | $672 |
Paid to pharmacies, not to this prescriber.
Other gynecology in Newport Beach
- Nkiruka ChubaNewport Beach$7K
- Christine ChaiNewport Beach$4K
- Bruce LeeMonterey$2.8M
- Barbara Levyla Jolla$719K
- Samar NahasRiverside$132K
- Aarathi CholkeriEl Segundo$128K
- Kelly WrightLos Angeles$119K
- Naphthali AlinsodLaguna Beach$108K
- Albertine OmaniOakland$70K
- Matthew SiedhoffBeverly Hills$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.